Vivani Medical, Inc. (VANI)
Market Cap | 107.82M |
Revenue (ttm) | n/a |
Net Income (ttm) | -25.37M |
Shares Out | 54.98M |
EPS (ttm) | -0.49 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 116,974 |
Open | 1.910 |
Previous Close | 1.910 |
Day's Range | 1.880 - 1.980 |
52-Week Range | 0.840 - 7.800 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 13, 2024 |
About VANI
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an e... [Read more]
Financial Performance
Financial StatementsNews
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...
Vivani Medical to Present at TIDES Conference 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...
Vivani Medical (VANI) stock price surged: is it a good buy?
Vivani Medical (NASDAQ: VANI) stock price surged hard this week after the company published positive results of its ongoing weight loss drug trial. The shares surged from about $1 and reached a high o...
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...
Vivani Medical to Present at BIO Investor Forum
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implan...
Vivani Medical to Present at the Boulder Peptide Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implan...
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, announced today that its...
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implan...
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI), an innovative, near-clinical stage biopharmaceutical company that is developing novel, miniature, long-term therapeutic implan...
Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, near clinical-stage biopharmaceutical company that develops novel, miniature, long-...
Vivani Medical Reports First Quarter Financial Results and Provides Business Update
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead produ...
Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent's Ongoing Orion Clinical Study
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an emerging biopharmaceutical company which develops miniaturized, subdermal implants today announ...
Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead produ...
Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic...
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including lead asse...
Vivani Medical to Present at the ThinkEquity Investor Conference
EMERYVILLE, Calif.
Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ: VANI) (the “Company” or “Vivani”) announced that trading of the Company's common stock on The N...